Tong Cheng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3179918/publications.pdf

Version: 2024-02-01

99 papers	2,161 citations	201674 27 h-index	302126 39 g-index
108 all docs	108 docs citations	108 times ranked	2554 citing authors

#	Article	IF	Citations
1	Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains. Human Vaccines and Immunotherapeutics, 2024, 17, 5334-5347.	3.3	1
2	Persisting lung pathogenesis and minimum residual virus in hamster after acute COVID-19. Protein and Cell, 2022, 13, 72-77.	11.0	6
3	Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters. Cellular and Molecular Immunology, 2022, 19, 290-292.	10.5	17
4	Development of a skin- and neuro-attenuated live vaccine for varicella. Nature Communications, 2022, 13, 824.	12.8	10
5	Female sex hormone, progesterone, ameliorates the severity of SARS-CoV-2-caused pneumonia in the Syrian hamster model. Signal Transduction and Targeted Therapy, 2022, 7, 47.	17.1	12
6	Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants. Cell Reports, 2022, 38, 110558.	6.4	15
7	Development of a rapid neutralization assay for the detection of neutralizing antibodies against coxsackievirus B1. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115676.	1.8	1
8	Rational Design of a Skin- and Neuro-Attenuated Live Varicella Vaccine: A Review and Future Perspectives. Viruses, 2022, 14, 848.	3.3	2
9	Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron. Cell Reports, 2022, 39, 110862.	6.4	9
10	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin, 2022, 67, 1372-1387.	9.0	54
11	PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron. Signal Transduction and Targeted Therapy, 2022, 7, .	17.1	8
12	Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein. Journal of Virological Methods, 2022, , 114564.	2.1	7
13	A uniform quantitative enzyme-linked immunosorbent assay for Coxsackievirus A16 antigen in vaccine. Human Vaccines and Immunotherapeutics, 2021, 17, 381-388.	3.3	2
14	A SCID mouse-human lung xenograft model of SARS-CoV-2 infection. Theranostics, 2021, 11, 6607-6615.	10.0	8
15	SARS-CoV-2 infection and disease outcomes in non-human primate models: advances and implications. Emerging Microbes and Infections, 2021, 10, 1881-1889.	6.5	10
16	Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating. Cell Host and Microbe, 2021, 29, 448-462.e5.	11.0	19
17	The prevalence of antibodies to SARS-CoV-2 among blood donors in China. Nature Communications, 2021, 12, 1383.	12.8	37
18	Gender associates with both susceptibility to infection and pathogenesis of SARS-CoV-2 in Syrian hamster. Signal Transduction and Targeted Therapy, 2021, 6, 136.	17.1	57

#	Article	IF	Citations
19	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Science Translational Medicine, 2021, 13, .	12.4	56
20	Development of A Neonatal Mouse Model for Coxsackievirus B1 Antiviral Evaluation. Virologica Sinica, 2021, 36, 1575-1584.	3.0	7
21	Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants. Nature Communications, 2021, 12, 5652.	12.8	49
22	Virusâ€Free and Liveâ€Cell Visualizing SARSâ€CoVâ€2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors. Small Methods, 2021, 5, 2001031.	8.6	25
23	A unique B cell epitope-based particulate vaccine shows effective suppression of hepatitis B surface antigen in mice. Gut, 2020, 69, 343-354.	12.1	34
24	Rapid Neutralization Testing System for Zika Virus Based on an Enzyme-Linked Immunospot Assay. ACS Infectious Diseases, 2020, 6, 811-819.	3.8	8
25	Near-atomic cryo-electron microscopy structures of varicella-zoster virus capsids. Nature Microbiology, 2020, 5, 1542-1552.	13.3	7
26	Animal models for emerging coronavirus: progress and new insights. Emerging Microbes and Infections, 2020, 9, 949-961.	6.5	50
27	DLL4 restores damaged liver by enhancing hBMSC differentiation into cholangiocytes. Stem Cell Research, 2020, 47, 101900.	0.7	8
28	Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16. Cell Host and Microbe, 2020, 27, 249-261.e5.	11.0	24
29	Liver chimeric mice with tupaia hepatocyte transplantation as an animal model for hepatitis B virus infection and antiviral therapy. Biosafety and Health, 2019, 1, 76-83.	2.7	0
30	A second open reading frame in human enterovirus determines viral replication in intestinal epithelial cells. Nature Communications, 2019, 10, 4066.	12.8	36
31	HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation. Gut, 2019, 68, 2044-2056.	12.1	46
32	Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus. Emerging Microbes and Infections, 2019, 8, 724-733.	6.5	3
33	Agonist c-Met Monoclonal Antibody Augments the Proliferation of hiPSC-derived Hepatocyte-Like Cells and Improves Cell Transplantation Therapy for Liver Failure in Mice. Theranostics, 2019, 9, 2115-2128.	10.0	11
34	Ferritin nanocage-based antigen delivery nanoplatforms: epitope engineering for peptide vaccine design. Biomaterials Science, 2019, 7, 1794-1800.	5.4	23
35	A potential therapeutic neutralization monoclonal antibody specifically against multi-coxsackievirus A16 strains challenge. Human Vaccines and Immunotherapeutics, 2019, 15, 2343-2350.	3.3	13
36	A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antiviral Research, 2019, 161, 28-35.	4.1	12

#	Article	IF	Citations
37	Development of an efficient neutralization assay for Coxsackievirus A10. Applied Microbiology and Biotechnology, 2019, 103, 1931-1938.	3.6	6
38	Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nature Microbiology, 2019, 4, 124-133.	13.3	40
39	Serological survey of neutralizing antibodies to eight major enteroviruses among healthy population. Emerging Microbes and Infections, 2018, 7, 1-15.	6.5	33
40	Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. Virology Journal, 2018, 15, 65.	3.4	15
41	Discovery and structural characterization of a therapeutic antibody against coxsackievirus A10. Science Advances, 2018, 4, eaat7459.	10.3	19
42	A Chimeric Humanized Mouse Model by Engrafting the Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cell for the Chronic Hepatitis B Virus Infection. Frontiers in Microbiology, 2018, 9, 908.	3.5	28
43	ER stress regulating protein phosphatase 2A-B56Î³, targeted by hepatitis B virus X protein, induces cell cycle arrest and apoptosis of hepatocytes. Cell Death and Disease, 2018, 9, 762.	6.3	29
44	Zika Virus Fatally Infects Wild Type Neonatal Mice and Replicates in Central Nervous System. Viruses, 2018, 10, 49.	3.3	39
45	Optimized HepaRG is a suitable cell source to generate the human liver chimeric mouse model for the chronic hepatitis B virus infection. Emerging Microbes and Infections, 2018, 7, 1-17.	6.5	12
46	Bioinspired Artificial Nanodecoys for Hepatitisâ€…B Virus. Angewandte Chemie - International Edition, 2018, 57, 12499-12503.	13.8	46
47	Bioinspired Artificial Nanodecoys for Hepatitisâ€…B Virus. Angewandte Chemie, 2018, 130, 12679-12683.	2.0	9
48	A novel toolbox for the in vitro assay of hepatitis D virus infection. Scientific Reports, 2017, 7, 40199.	3.3	3
49	A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus. Vaccine, 2017, 35, 2728-2735.	3.8	18
50	Herpes simplex virus type 1 abrogates the antiviral activity of Ch25h via its virion host shutoff protein. Antiviral Research, 2017, 143, 69-73.	4.1	23
51	A neonatal mouse model of coxsackievirus A10 infection for anti-viral evaluation. Antiviral Research, 2017, 144, 247-255.	4.1	25
52	ORF7 of Varicella-Zoster Virus Is Required for Viral Cytoplasmic Envelopment in Differentiated Neuronal Cells. Journal of Virology, 2017, 91, .	3.4	26
53	Outer nuclear membrane fusion of adjacent nuclei in varicella-zoster virus-induced syncytia. Virology, 2017, 512, 34-38.	2.4	6
54	A SCID mouse-human lung xenograft model of varicella-zoster virus infection. Antiviral Research, 2017, 146, 45-53.	4.1	6

#	Article	IF	Citations
55	Atomic structures of Coxsackievirus A6 and its complex with a neutralizing antibody. Nature Communications, 2017, 8, 505.	12.8	61
56	Varicella-zoster virus ORF7 interacts with ORF53 and plays a role in its trans-Golgi network localization. Virologica Sinica, 2017, 32, 387-395.	3.0	9
57	An HBV-tolerant immunocompetent model that effectively simulates chronic hepatitis B virus infection in mice. Experimental Animals, 2016, 65, 373-382.	1.1	4
58	Modulation of host CD59 expression by varicella-zoster virus in human xenografts in vivo. Virology, 2016, 491, 96-105.	2.4	8
59	A neonatal mouse model for the evaluation of antibodies and vaccines against coxsackievirus A6. Antiviral Research, 2016, 134, 50-57.	4.1	26
60	Detection and analysis of tupaia hepatocytes via mAbs against tupaia serum albumin. Experimental Animals, 2016, 65, 117-123.	1.1	2
61	Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay. Applied Microbiology and Biotechnology, 2016, 100, 9321-9329.	3.6	6
62	A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice. Vaccine, 2016, 34, 5938-5945.	3.8	12
63	Serological Evaluation of Immunity to the Varicella-Zoster Virus Based on a Novel Competitive Enzyme-Linked Immunosorbent Assay. Scientific Reports, 2016, 6, 20577.	3.3	9
64	Functional analysis of human cytomegalovirus UL/bâ€² region using SCID-hu mouse model. Journal of Medical Virology, 2016, 88, 1417-1426.	5.0	7
65	Development of sandwich ELISAs that can distinguish different types of coxsackievirus A16 viral particles. Applied Microbiology and Biotechnology, 2016, 100, 2809-2815.	3.6	8
66	A highly conserved epitope-vaccine candidate against varicella-zoster virus induces neutralizing antibodies in mice. Vaccine, 2016, 34, 1589-1596.	3.8	13
67	Development and evaluation of rapid point-of-care tests for detection of Enterovirus 71 and Coxsackievirus A16 specific immunoglublin M antibodies. Journal of Virological Methods, 2016, 231, 44-47.	2.1	14
68	Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen. Gut, 2016, 65, 658-671.	12.1	104
69	A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71. Scientific Reports, 2015, 5, 12973.	3.3	35
70	Development of a coxsackievirus A16 neutralization test based on the enzyme-linked immunospot assay. Journal of Virological Methods, 2015, 215-216, 56-60.	2.1	11
71	Insights into the function of tegument proteins from the varicella zoster virus. Science China Life Sciences, 2015, 58, 739-749.	4.9	7
72	Construction and characterization of an infectious cDNA clone of Echovirus 25. Virus Research, 2015, 205, 41-44.	2.2	9

#	Article	IF	Citations
73	A monoclonal antibody-based VZV glycoprotein E quantitative assay and its application on antigen quantitation in VZV vaccine. Applied Microbiology and Biotechnology, 2015, 99, 4845-4853.	3.6	14
74	Construction and characterization of an infectious clone of coxsackievirus A6 that showed high virulence in neonatal mice. Virus Research, 2015, 210, 165-168.	2.2	21
75	Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 8427-8432.	7.1	43
76	In Vivo Time-Related Evaluation of a Therapeutic Neutralization Monoclonal Antibody against Lethal Enterovirus 71 Infection in a Mouse Model. PLoS ONE, 2014, 9, e109391.	2.5	14
77	Protection against Lethal Enterovirus 71 Challenge in Mice by a Recombinant Vaccine Candidate Containing a Broadly Cross-Neutralizing Epitope within the VP2 EF Loop. Theranostics, 2014, 4, 498-513.	10.0	52
78	Development of an Enzyme-Linked Immunosorbent Spot Assay To Measure Serum-Neutralizing Antibodies against Coxsackievirus B3. Vaccine Journal, 2014, 21, 312-320.	3.1	15
79	Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay. Journal of Virological Methods, 2014, 200, 10-14.	2.1	9
80	Analysis of Cross-Reactive Neutralizing Antibodies in Human HFMD Serum with an EV71 Pseudovirus-Based Assay. PLoS ONE, 2014, 9, e100545.	2.5	29
81	Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: Current genotyping of EV71 does not reflect their antigenicity. Vaccine, 2013, 31, 425-430.	3.8	41
82	Development of a novel baculovirus titration method using the Enzyme-linked immunosorbent spot (ELISPOT) assay. Journal of Virological Methods, 2013, 188, 114-120.	2.1	11
83	The Cross-Neutralizing Activity of Enterovirus 71 Subgenotype C4 Vaccines in Healthy Chinese Infants and Children. PLoS ONE, 2013, 8, e79599.	2.5	62
84	ORF7 of Varicella-Zoster Virus Is a Neurotropic Factor. Journal of Virology, 2012, 86, 8614-8624.	3.4	44
85	Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. Virology Journal, 2012, 9, 118.	3.4	21
86	Development of an IgM-capture ELISA for Coxsackievirus A16 infection. Journal of Virological Methods, 2011, 171, 107-110.	2.1	18
87	RNA Interference inhibits Hepatitis B Virus of different genotypes in Vitro and in Vivo. BMC Microbiology, 2010, 10, 214.	3.3	23
88	Performance of Detecting IgM Antibodies against Enterovirus 71 for Early Diagnosis. PLoS ONE, 2010, 5, e11388.	2.5	44
89	Genome-Wide Mutagenesis Reveals That ORF7 Is a Novel VZV Skin-Tropic Factor. PLoS Pathogens, 2010, 6, e1000971.	4.7	105
90	Tetracysteine as a Reporter for Gene Therapy. Biomedical and Environmental Sciences, 2009, 22, 496-501.	0.2	2

#	Article	IF	Citations
91	Immune Response Induced by a Different Combined Immunization of HBsAg Vaccine. Intervirology, 2007, 50, 336-340.	2.8	0
92	Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity. Molecular Immunology, 2007, 44, 3261-3266.	2.2	22
93	RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells. Chinese Journal of Digestive Diseases, 2006, 7, 230-236.	1.0	6
94	Variants of Green Fluorescent Protein GFPxm. Marine Biotechnology, 2006, 8, 560-566.	2.4	11
95	Variants of Green Fluorescent Protein GFPxm. Marine Biotechnology, 2006, 8, 560.	2.4	1
96	Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus. World Journal of Gastroenterology, 2005, 11, 492.	3.3	17
97	Hydrophobicity of reactive site loop of SCCA1 affects its binding to hepatitis B virus. World Journal of Gastroenterology, 2005, 11, 2864.	3.3	0
98	A rapid and efficient method to express target genes in mammalian cells by baculovirus. World Journal of Gastroenterology, 2004, 10, 1612.	3.3	47
99	Oral immunization of animals with transgenic cherry tomatillo expressing HBsAg. World Journal of Gastroenterology, 2003, 9, 996.	3.3	68